COMMENTARY

European Society of Cardiology (ESC) Congress 2020 Highlights: Drugs Old and New

; Bruce Jancin; Tricia Ward; Patrice Wendling; Mitchel Zoler. Video Editor: John Rodriguez

Disclosures

October 12, 2020

Related News and Commentary Stories

EMPEROR-Reduced: Empagliflozin's HFrEF Benefit Solidifies Class Effects

SGLT2 Inhibitors in HFrEF: Putting EMPEROR-Reduced in Context

Aspirin Alone Preferred Antithrombotic Strategy After TAVI

LoDoCo2: Added Steam for Colchicine as Secondary Prevention

DAPA-CKD: SGLT2 Inhibitor Benefit Extends to Chronic Kidney Disease Without Diabetes

DAPA-CKD: SGLT2 Inhibitors 'The Beta-Blockers for the Kidneys'

Follow theheart.org | Medscape Cardiology on Twitter

Follow Medscape on Facebook, Twitter, Instagram, and YouTube

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....